Exploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR) T cell therapy is effective against blood cancers but limited in solid tumors.
• Epidermal growth factor receptor (EGFR) is a target in several solid tumors.
• Novel strategies are needed to adapt CAR T cell therapy for solid tumors.

Purpose of the Study:

• To investigate CAR-engineered peripheral blood mononuclear cells (PBMCs) for treating EGFR-positive solid tumors.
• To assess the efficacy and specificity of anti-EGFR CAR-PBMCs.
• To evaluate CAR-PBMCs as a potential adoptive cell therapy.

Main Methods:

• Generated anti-EGFR second-generation CAR-effector cells via lentiviral transduction of PBMCs.
• Stimulated transduced PBMCs with cytokines and CD3/CD28 beads to enhance activation and proliferation.
• Assessed CAR-PBMC cytotoxicity against EGFR-positive cancer cell lines using flow cytometry and real-time cell analysis.

Main Results:

• CAR-PBMCs showed enhanced targeting and cytotoxicity against EGFR-positive cancer cell lines (MDA-MB-468, SK-BR-3).
• CAR-PBMC activity was significantly higher compared to untransduced controls.
• No significant cytotoxic effects were observed on allogeneic PBMCs, indicating specificity.

Conclusions:

• CAR-engineered PBMCs represent a promising therapeutic approach for EGFR-positive solid tumors.
• The study supports further clinical investigation of CAR-PBMC therapy.
• This strategy offers potential for treating difficult-to-treat solid tumor cancers.